Immatics NV (IMTX)
12.00
-0.20
(-1.60%)
USD |
NASDAQ |
Jun 25, 16:00
12.00
0.00 (0.00%)
After-Hours: 19:23
Immatics Research and Development Expense (Annual): 128.47M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 128.47M |
| December 31, 2022 | 112.61M |
| December 31, 2021 | 103.62M |
| Date | Value |
|---|---|
| December 31, 2020 | 76.61M |
| December 31, 2019 | 44.88M |
| December 31, 2018 | 40.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
44.88M
Minimum
2019
128.47M
Maximum
2023
93.24M
Average
103.62M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Affimed NV | 102.80M |
| InflaRx NV | 44.41M |
| MorphoSys AG | 307.04M |
| BioNTech SE | 1.930B |
| CureVac NV | 125.28M |